Navigation Links
Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
Date:8/8/2008

physiologic

prandial (mealtime) insulin release and activity than Humulin R or

Humalog alone. Statistically significant pharmacokinetic (PK) and

glucodynamic (GD) improvements observed in the study include:

Significantly faster systemic absorption of each insulin starting with

the first observation time point of three minutes after injection,

faster and greater glucose lowering activity early after injection,

greater peak insulin levels for the same dose administered, lower

variability of key PK and GD variables across subjects, and improvement

for rHuPH20 in combination with Humulin across all parameters when

compared to Humalog alone.

-- Release of Chemophase(R) Phase I/IIa clinical results from a continuing

clinical trial in the treatment of superficial bladder cancer. Based

on the results, the Chemophase combination treatment of mitomycin plus

the rHuPH20 enzyme was well tolerated and appears safe. The study

reported no dose-limiting toxicities and no observed side effects

attributable to the enzyme, and established the dose for subsequent

clinical trials, therefore achieving the pre-defined primary objective

of the study. In addition, there were no neutralizing antibodies to

rHuPH20 detected and the plasma concentration of mitomycin was either

non-measureable or negligible and well below the threshold that may be

predictive for myelosuppression (a decrease in bone marrow activity,

resulting in fewer red blood cells, white blood cells, and platelets).

-- New findings of positive pre-clinical animal efficacy data for

pegylated-rHuPH20 enzyme (PEGPH20) at the American Association for

Cancer Research (AACR) Translational Cancer Medicine meeting in

Monterey, CA. The study showed that treatment of hormone resistant

human prostat
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
2. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
3. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
4. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
5. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
8. Halozyme Therapeutics Amends Stockholder Rights Plan
9. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
10. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
11. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... GMO corn cases filed across the ... in the process of being consolidated in a Kansas ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... District of Kansas. , Management of the Syngenta GMO ... U.S. District Judge John W. Lungstrum.* , As a ...
(Date:12/24/2014)... December 23, 2014 According to Ross Selinger, ... Affiliate of ITRA Global, the national office market continues to ... This is evidenced by the third quarter’s surprising 3.9% ... Low energy costs have held inflation down and the ... is the housing market remaining soft. , This solid economic ...
(Date:12/24/2014)... Diego, CA (PRWEB) December 23, 2014 ... where their Twitter followers can submit their #HolidayInTheLab ... themselves and their lab mates. , For those struggling ... lab mates, the Pipette.com Holiday in the Lab Contest ... Pipette.com Twitter followers to send pictures of ...
(Date:12/24/2014)... 2014 Sigma-Aldrich Corporation (NASDAQ: ... under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) ... 22, 2014, thereby completing the U.S. HSR Act ... of the Company by Merck KGaA, Darmstadt, Germany.  ... condition to closing the transaction, which remains subject ...
Breaking Biology Technology:Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3
... Recognized for Development of Statistical Methods and SoftwareSAN DIEGO, ... and of Health Research & Policy at Stanford ... Academy of Sciences. Election to the National Academy ... can be accorded to a scientist in the US ...
... published,today in the online edition of Nature Genetics, scientists ... from Iceland, Denmark and the,Netherlands present the discovery of ... (SNPs) that influence the age of girls at menarche, ... by both genetic,and environmental factors, though the SNPs reported ...
... naturally occurring elements, add another to the list of those ... physics in Arts & Sciences at Washington University in St. ... the time discovered that europium becomes superconducting at 1.8 ... making it the 53rd known elemental superconductor and the 23rd ...
Cached Biology Technology:Professor Wing Wong Elected to the National Academy of Sciences 2deCODE Study Shows Complex Interplay of the Human Biological Clock With Height, Weight and Disease 2deCODE Study Shows Complex Interplay of the Human Biological Clock With Height, Weight and Disease 3deCODE Study Shows Complex Interplay of the Human Biological Clock With Height, Weight and Disease 4Europium discovery 2Europium discovery 3
(Date:12/22/2014)... 22, 2014 Research and Markets ... addition of the "The Global Watermarking ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... overview of the global digital media watermarking ... and monitor piracy by securely and invisibly ...
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ... team and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... addition of the "Global Chemical Sensor Market ... http://photos.prnewswire.com/prnh/20130307/600769 One ... increasing demand for medical sensors in biomedical applications. ... for quick and correct diagnosis during surgical procedures. ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... FORT COLLINS - In the last 50 years, modern ... of today,s veterinary and human medicine students still hone ... pig,s feet before transitioning to a live patient. An ... artificial body parts that look, feel, behave, and even ...
... been at least a billion years since plants and ... eons shared a common threat in the form of ... in remarkably similar mechanisms for detecting the molecular signatures ... treatment of infectious diseases in humans. The recognition ...
... produce many antibodies against the protein encapsulating the virus, most ... A new study suggests why some of the most common ... a form it takes after the virus has already invaded ... Hospital Boston and their colleagues. The findings, published ...
Cached Biology News:Invention helps students learn surgical techniques before operating on patients 2Reading the signs: Plants and animals found common ground in response to microbial threats 2Designing more effective anti-HIV antibodies 2Designing more effective anti-HIV antibodies 3